These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 10854571)

  • 1. 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells.
    Lamensdorf I; Eisenhofer G; Harvey-White J; Nechustan A; Kirk K; Kopin IJ
    Brain Res; 2000 Jun; 868(2):191-201. PubMed ID: 10854571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde.
    Lamensdorf I; Eisenhofer G; Harvey-White J; Hayakawa Y; Kirk K; Kopin IJ
    J Neurosci Res; 2000 May; 60(4):552-8. PubMed ID: 10797558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.
    Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Kopin IJ; Sharabi Y
    J Neurochem; 2015 Apr; 133(1):14-25. PubMed ID: 25645689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate.
    Jinsmaa Y; Florang VR; Rees JN; Anderson DG; Strack S; Doorn JA
    Chem Res Toxicol; 2009 May; 22(5):835-41. PubMed ID: 19388687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity of a treatment associating dopamine and disulfiram for catecholaminergic neuroblastoma SH-SY5Y cells: relationships with 3,4-dihydroxyphenylacetaldehyde formation.
    Legros H; Dingeval MG; Janin F; Costentin J; Bonnet JJ
    Neurotoxicology; 2004 Mar; 25(3):365-75. PubMed ID: 15019299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3,4-Dihydroxyphenylethanol (Hydroxytyrosol) Mitigates the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells.
    Goldstein DS; Jinsmaa Y; Sullivan P; Holmes C; Kopin IJ; Sharabi Y
    Neurochem Res; 2016 Sep; 41(9):2173-8. PubMed ID: 27220335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease.
    Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Sullivan R; Gross DJ; Holmes C; Kopin IJ; Sharabi Y
    J Neurochem; 2012 Dec; 123(6):932-43. PubMed ID: 22906103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the oxidative metabolism of 3,4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal.
    Florang VR; Rees JN; Brogden NK; Anderson DG; Hurley TD; Doorn JA
    Neurotoxicology; 2007 Jan; 28(1):76-82. PubMed ID: 16956664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.
    Goldstein DS; Sullivan P; Holmes C; Miller GW; Alter S; Strong R; Mash DC; Kopin IJ; Sharabi Y
    J Neurochem; 2013 Sep; 126(5):591-603. PubMed ID: 23786406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylmercury impairs canonical dopamine metabolism in rat undifferentiated pheochromocytoma (PC12) cells by indirect inhibition of aldehyde dehydrogenase.
    Tiernan CT; Edwin EA; Hawong HY; Ríos-Cabanillas M; Goudreau JL; Atchison WD; Lookingland KJ
    Toxicol Sci; 2015 Apr; 144(2):347-56. PubMed ID: 25601988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.
    Goldstein DS; Jinsmaa Y; Sullivan P; Holmes C; Kopin IJ; Sharabi Y
    J Pharmacol Exp Ther; 2016 Feb; 356(2):483-92. PubMed ID: 26574516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydroxyphenylacetaldehyde Lowering Treatment Improves Locomotor and Neurochemical Abnormalities in the Rat Rotenone Model: Relevance to the Catecholaldehyde Hypothesis for the Pathogenesis of Parkinson's Disease.
    Khashab R; Gutman-Sharabi N; Shabtai Z; Landau R; Halperin R; Fay-Karmon T; Leibowitz A; Sharabi Y
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid peroxidation products inhibit dopamine catabolism yielding aberrant levels of a reactive intermediate.
    Rees JN; Florang VR; Anderson DG; Doorn JA
    Chem Res Toxicol; 2007 Oct; 20(10):1536-42. PubMed ID: 17887726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria.
    Kristal BS; Conway AD; Brown AM; Jain JC; Ulluci PA; Li SW; Burke WJ
    Free Radic Biol Med; 2001 Apr; 30(8):924-31. PubMed ID: 11295535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know.
    Goldstein DS
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldehyde dehydrogenase inhibition generates a reactive dopamine metabolite autotoxic to dopamine neurons.
    Doorn JA; Florang VR; Schamp JH; Vanle BC
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1(0 1):S73-5. PubMed ID: 24262193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rat rotenone model reproduces the abnormal pattern of central catecholamine metabolism found in Parkinson's disease.
    Landau R; Halperin R; Sullivan P; Zibly Z; Leibowitz A; Goldstein DS; Sharabi Y
    Dis Model Mech; 2022 Jan; 15(1):. PubMed ID: 34842277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural Features and Toxicity of α-Synuclein Oligomers Grown in the Presence of DOPAC.
    Palazzi L; Fongaro B; Leri M; Acquasaliente L; Stefani M; Bucciantini M; Polverino de Laureto P
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis.
    Burke WJ; Li SW; Williams EA; Nonneman R; Zahm DS
    Brain Res; 2003 Nov; 989(2):205-13. PubMed ID: 14556942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Semi-chronic increase in striatal level of 3,4-dihydroxyphenylacetaldehyde does not result in alteration of nigrostriatal dopaminergic neurones.
    Legros H; Janin F; Dourmap N; Bonnet JJ; Costentin J
    J Neurosci Res; 2004 Feb; 75(3):429-35. PubMed ID: 14743456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.